The JADE trial enrolled 164 U.S. patients who initially received three monthly doses of OLN324 or faricimab, followed by 12 weeks off treatment with retreatment allowed only if disease recurred
Its a major breakthrough for women’s ovarian cancer care in Europe
The impact on Phase III trials is particularly significant, as these later-stage studies involve larger, committed patient populations and represent years of investment
Lonza will take on technology transfer, process optimization, and cGMP manufacturing, leveraging its global network and expertise in highly potent compounds
Capital infusion to accelerate Earendil’s R&D platform
The collaboration highlights the rising importance of intranasal delivery in developing non-vaccine approaches to respiratory disease prevention
The framework introduces 15 consensus terms and definitions grouped across four core dimensions of skin health
At the center of the announcement are two late-breaking studies that could reshape treatment approaches for patients with high cholesterol and a complex form of heart failure
The move comes as China rapidly expands its capabilities in the pharmaceutical sector, particularly in licensing and drug development
The biotechnology company will tap into Catalent’s expertise in induced pluripotent stem cells and advanced cell-therapy manufacturing
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
